Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

YoungTae Kim, Sang Wun Kim, Bo Sung Yoon, Hye Jin Cho, Eun Ji Nahm, Sung Hoon Kim, Jae-Hoon Kim, Jae Wook Kim

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.

Original languageEnglish
Pages (from-to)199-204
Number of pages6
JournalGynecologic Oncology
Volume105
Issue number1
DOIs
Publication statusPublished - 2007 Apr 1

Fingerprint

saccharated ferric oxide
Chemoradiotherapy
Uterine Cervical Neoplasms
Anemia
Blood Transfusion
Control Groups

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Kim, YoungTae ; Kim, Sang Wun ; Yoon, Bo Sung ; Cho, Hye Jin ; Nahm, Eun Ji ; Kim, Sung Hoon ; Kim, Jae-Hoon ; Kim, Jae Wook. / Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. In: Gynecologic Oncology. 2007 ; Vol. 105, No. 1. pp. 199-204.
@article{fd76e67558d944d1b6a45f5c7a45c159,
title = "Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy",
abstract = "Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50{\%}. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0{\%}) patients required blood transfusions, whereas 29 (64.0{\%}) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.",
author = "YoungTae Kim and Kim, {Sang Wun} and Yoon, {Bo Sung} and Cho, {Hye Jin} and Nahm, {Eun Ji} and Kim, {Sung Hoon} and Jae-Hoon Kim and Kim, {Jae Wook}",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.ygyno.2006.11.014",
language = "English",
volume = "105",
pages = "199--204",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. / Kim, YoungTae; Kim, Sang Wun; Yoon, Bo Sung; Cho, Hye Jin; Nahm, Eun Ji; Kim, Sung Hoon; Kim, Jae-Hoon; Kim, Jae Wook.

In: Gynecologic Oncology, Vol. 105, No. 1, 01.04.2007, p. 199-204.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

AU - Kim, YoungTae

AU - Kim, Sang Wun

AU - Yoon, Bo Sung

AU - Cho, Hye Jin

AU - Nahm, Eun Ji

AU - Kim, Sung Hoon

AU - Kim, Jae-Hoon

AU - Kim, Jae Wook

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.

AB - Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=33947312849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947312849&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.11.014

DO - 10.1016/j.ygyno.2006.11.014

M3 - Article

C2 - 17234260

AN - SCOPUS:33947312849

VL - 105

SP - 199

EP - 204

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -